CLAIMS:

1. A method of producing an immunogenic and mutant *Clostridium difficile* toxin comprising contacting a peptide derived from a *Clostridium difficile* toxin with 1-Ethyl-3-(3-Dimethylaminopropyl)-Carbodiimide (EDC) for at most 2 hours, contacting the peptide with N-hydroxysuccinimide (NHS); and purifying the EDC-contacted and NHS-contacted peptide, wherein the step of purifying comprises filtration.

2. The method of claim 1, further comprising contacting the peptide with glycine.

3. The method of claim 1, further comprising contacting the peptide with alanine or glycine methyl ester.

4. The method of claim 1, wherein the peptide comprises at least one lysine residue.

5. The method of claim 1, wherein the peptide comprises at least one aspartic acid residue or at least one glutamic acid residue.

6. The method of claim 1, wherein the peptide comprises at least 500 contiguous amino acids of SEQ ID NO: 1 or at least 500 contiguous amino acids of SEQ ID NO: 2.

7. The method of claim 6, further comprising contacting a second peptide, having at least 500 contiguous amino acids of SEQ ID NO: 1 or at least 500 contiguous amino acids of SEQ ID NO: 2, with 1-Ethyl-3-(3-Dimethylaminopropyl)-Carbodiimide (EDC).

8. The method of claim 1, wherein the peptide comprises at least one mutation relative to the corresponding wild-type *Clostridium difficile* toxin.

9. The method of claim 1, wherein the peptide comprises the amino acid sequence set forth in SEQ ID NO: 4, wherein the methionine at position 1 is not present.

10. The method of claim 1, wherein the peptide comprises the amino acid sequence set forth in SEQ ID NO: 6, wherein the methionine at position 1 is not present.

11. A method of producing an immunogenic and mutant *Clostridium difficile* toxin comprising contacting a peptide derived from a *Clostridium difficile* toxin with 1-Ethyl-3-(3-Dimethylaminopropyl)-Carbodiimide (EDC), contacting the peptide with N-hydroxysuccinimide (NHS); further contacting the peptide with glycine; and purifying the EDC-contacted, NHS-contacted, and glycine-contacted peptide, wherein the step of purifying comprises filtration.

12. The method of claim 11, wherein the contacting occurs for at most 2 hours.

13. The method of claim 11, wherein the peptide comprises at least one lysine residue.

14. The method of claim 11, wherein the peptide comprises at least one aspartic acid residue or at least one glutamic acid residue.

15. The method of claim 11, wherein the peptide comprises at least 500 contiguous amino acids of SEQ ID NO: 1 or at least 500 contiguous amino acids of SEQ ID NO: 2.

16. The method of claim 15, further comprising contacting a second peptide, having at least 500 contiguous amino acids of SEQ ID NO: 1 or at least 500 contiguous amino acids of SEQ ID NO: 2, with 1-Ethyl-3-(3-Dimethylaminopropyl)-Carbodiimide (EDC).

17. The method of claim 11, wherein the peptide comprises at least one mutation relative to the corresponding wild-type *Clostridium difficile* toxin.

18. The method of claim 11, wherein the peptide comprises the amino acid sequence set forth in SEQ ID NO: 4, wherein the methionine at position 1 is not present.

19. The method of claim 11, wherein the peptide comprises the amino acid sequence set forth in SEQ ID NO: 6, wherein the methionine at position 1 is not present.

20. A method of producing an immunogenic and mutant *Clostridium difficile* toxin comprising contacting a peptide derived from a *Clostridium difficile* toxin with 1-Ethyl-3-(3-Dimethylaminopropyl)-Carbodiimide (EDC), contacting the peptide with N-hydroxysuccinimide (NHS); further contacting the peptide with alanine or glycine methyl ester; and purifying the EDC-contacted, NHS-contacted, and alanine- or glycine methyl ester-contacted peptide, wherein the step of purifying comprises filtration.

21. The method of claim 20, wherein the contacting occurs for at most 2 hours.

22. The method of claim 20, wherein the peptide comprises at least one lysine residue.

23. The method of claim 20, wherein the peptide comprises at least one aspartic acid residue or at least one glutamic acid residue.

24. The method of claim 20, wherein the peptide comprises at least 500 contiguous amino acids of SEQ ID NO: 1 or at least 500 contiguous amino acids of SEQ ID NO: 2.

25. The method of claim 24, further comprising contacting a second peptide, having at least 500 contiguous amino acids of SEQ ID NO: 1 or at least 500 contiguous amino acids of SEQ ID NO: 2, with 1-Ethyl-3-(3-Dimethylaminopropyl)-Carbodiimide (EDC).

26. The method of claim 20, wherein the peptide comprises at least one mutation relative to the corresponding wild-type *Clostridium difficile* toxin.

27. The method of claim 20, wherein the peptide comprises the amino acid sequence set forth in SEQ ID NO: 4, wherein the methionine at position 1 is not present.

28. The method of claim 20, wherein the peptide comprises the amino acid sequence set forth in SEQ ID NO: 6, wherein the methionine at position 1 is not present.